Free tool
FAERS Monitor: Voriconazole
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208562 or its brand name (Voriconazole, Voriconazole). Reports on generic versions are filed under their own applications.
Reports
22,090
Serious
20,722
94% of reports
Hospitalization
9,197
Death reported
6,438
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,031
- off label use2,121
- drug interaction2,063
- pyrexia1,074
- pneumonia911
- bronchopulmonary aspergillosis897
- condition aggravated879
- aspergillus infection866
- febrile neutropenia756
- death727
- respiratory failure692
- multiple organ dysfunction syndrome667
- product use in unapproved indication667
- neutropenia618
- septic shock602
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 89 |
| 2005 | 108 |
| 2006 | 113 |
| 2007 | 193 |
| 2008 | 210 |
| 2009 | 294 |
| 2010 | 359 |
| 2011 | 388 |
| 2012 | 429 |
| 2013 | 495 |
| 2014 | 459 |
| 2015 | 570 |
| 2016 | 798 |
| 2017 | 1,417 |
| 2018 | 1,785 |
| 2019 | 1,949 |
| 2020 | 1,988 |
| 2021 | 1,919 |
| 2022 | 1,945 |
| 2023 | 1,831 |
| 2024 | 1,790 |
| 2025 | 1,733 |
| 2026 | 1,227 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,069 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aspergillus infectionSignal | 866 | 144.6 | 134.7 | 107,092 |
| bronchopulmonary aspergillosisSignal | 897 | 124.4 | 116.2 | 97,042 |
| multiple organ dysfunction syndromeSignal | 667 | 22.9 | 21.3 | 13,661 |
| septic shockSignal | 602 | 13.3 | 12.3 | 6,782 |
| drug interactionSignal | 2,063 | 12.5 | 12.0 | 21,759 |
| febrile neutropeniaSignal | 756 | 11.0 | 10.2 | 6,780 |
| respiratory failureSignal | 692 | 9.1 | 8.5 | 4,959 |
| neutropeniaSignal | 618 | 4.3 | 4.0 | 1,590 |
| pyrexiaSignal | 1,074 | 3.0 | 2.8 | 1,412 |
| drug ineffectiveSignal | 4,031 | 2.9 | 2.8 | 5,403 |
| condition aggravatedSignal | 879 | 2.8 | 2.6 | 995 |
| pneumoniaSignal | 911 | 2.7 | 2.5 | 973 |
| product use in unapproved indicationSignal | 667 | 2.6 | 2.4 | 642 |
| off label useSignal | 2,121 | 2.3 | 2.2 | 1,638 |
| death | 727 | 0.8 | 0.7 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.